NCI-2021-09616

A Phase 1b/2 trial of Dupilumab given in conjunction with PD-(L)1 blockade in the treatment of relapsed/refractory metastatic NSCLC.

This trial investigates the effectiveness of Dupilumab, a medication that targets specific proteins invovled in inflammation, in combination with PD-L1 blockade, an immunotherapy medication, for treating relapsed/refractory metastatic non-small cell lung cancer (NSCLC). The study aims to determine how well the combination treatment works and its safety.

PD-L1: PD-L1 is a protein that regulates the immune system's response to cancer cells, and helps cancer cells hide from the body's immune system.

immunotherapy: The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

non-small cell lung cancer: A type of lung cancer with non small cells that grow too much and can spread to other parts of the body

refractory: Cancer that does not respond to treatment is called refractory and can be known as resistant cancer. The cancer may be resistant to therapy at the beginning of treatment or during treatment.

metastatic: cancer that has spread from its original location or organ to other parts of the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05013450

Clinical Trial Site: Sinai

To see all available clinical trials click here.